OBJECTIVE The islet in type 2 diabetes is characterized by β-cell apoptosis, β-cell endoplasmic reticulum stress, and islet amyloid deposits derived from islet amyloid polypeptide (IAPP). Toxic oligomers of IAPP form intracellularly in β-cells in humans with type 2 diabetes, suggesting impaired clearance of misfolded proteins. In this study, we investigated whether human-IAPP (h-IAPP) disrupts the endoplasmic reticulum–associated degradation/ubiquitin/proteasome system.
RESEARCH DESIGN AND METHODS We used pancreatic tissue from humans with and without type 2 diabetes, isolated islets from h-IAPP transgenic rats, isolated human islets, and INS 832/13 cells transduced with adenoviruses expressing either h-IAPP or a comparable expression of rodent-IAPP. Immunofluorescence and Western blotting were used to detect polyubiquitinated proteins and ubiquitin carboxyl-terminal hydrolase L1 (UCH-L1) protein levels. Proteasome activity was measured in isolated rat and human islets. UCH-L1 was knocked down by small-interfering RNA in INS 832/13 cells and apoptosis was evaluated.
RESULTS We report accumulation of polyubiquinated proteins and UCH-L1 deficiency in β-cells of humans with type 2 diabetes. These findings were reproduced by expression of oligomeric h-IAPP but not soluble rat-IAPP. Downregulation of UCH-L1 expression and activity to reproduce that caused by h-IAPP in β-cells induced endoplasmic reticulum stress leading to apoptosis.
CONCLUSIONS Our results indicate that defective protein degradation in β-cells in type 2 diabetes can, at least in part, be attributed to misfolded h-IAPP leading to UCH-L1 deficiency, which in turn further compromises β-cell viability.
Type 2 diabetes is characterized by a progressive decline in β-cell function in the face of insulin resistance. Although the mechanisms underlying β-cell dysfunction are unknown, it is likely related to the presence of β-cell endoplasmic reticulum (ER) stress (1,2), increased β-cell apoptosis (3,4), and decreased β-cell mass (3,5). The islet in type 2 diabetes is also characterized by amyloid deposits derived from islet amyloid polypeptide (IAPP) (3). Insulin resistance, the most important risk factor for development of type 2 diabetes, induces increased β-cell expression of insulin but to an even greater extent IAPP (6,7).
IAPP is a 37–amino acid peptide that is coexpressed and cosecreted with insulin (8). This peptide has the propensity to form amyloid fibrils in species at risk of spontaneously developing diabetes (e.g., nonhuman primates and cats). In contrast, in rodents, IAPP is not amyloidogenic because of proline residue substitutions, and rodents do not spontaneously develop type 2 diabetes with the islet morphology present in humans (9). However, increased expression of human-IAPP (h-IAPP) in rodents may lead to type 2 diabetes with islet pathology comparable to that in humans (10–14). Intracellular IAPP toxic oligomers and ER stress have been reported in β-cells of both humans with type 2 diabetes and rodents with high expression of h-IAPP (1,15,16).
The ER is responsible for synthesis, folding, and maturation of proteins. It is endowed with a quality-control system that facilitates the recognition of misfolded proteins and targets them for degradation by the ubiquitin/proteasome system (17). Efficient removal of misfolded proteins by the endoplasmic reticulum–associated degradation (ERAD) is essential to protect cells from ER stress. This is accomplished by several distinct steps. First, if a protein fails quality control, it is removed from the ER by retrograde translocation. Second, multiple ubiquitin molecules are covalently attached to the targeted protein. Third, the polyubiquinated protein is relocated to the 26S proteasome. Fourth, the ubiquitin chains are removed from the misfolded protein by a deubiquitinating enzyme, and thus it is finally rendered available for degradation by the passage through the 26S proteasome (18).
We recently reported that accumulation of polyubiquitinated proteins occurs in pancreatic islets of h-IAPP transgenic mice but not in mice with comparable transgenic expression of rodent-IAPP (r-IAPP) (16). This implies that increased expression of h-IAPP may interfere with the ERAD/ubiquitin/proteasome system, and thus contribute to β-cell ER stress. β-Cells in type 2 diabetes share many characteristics of neurons in neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases, also characterized by protein misfolding, formation of toxic oligomers of locally expressed amyloidogenic proteins, and proteotoxicity prompting ER stress (9,19). These observations imply that the mechanisms that defend against accumulation of misfolded proteins may be disrupted in β-cells in type 2 diabetes as previously documented in neurodegenerative diseases (19–23). Of interest, impairment of the ubiquitin/proteasome pathway has been shown to contribute to neurotoxicity in some neurodegenerative diseases (20–23). In particular, deficiency in ubiquitin carboxyl-terminal hydrolase L1 (UCH-L1) has been observed in the brains of individuals with Alzheimer's and Parkinson's diseases (24). UCH-L1, a member of the deubiquinating enzyme family, is abundantly expressed in β-cells (25) and neurons (26). UCH-L1 is required to hydrolyze ubiquitin chains leading to both the release of protein targeted for degradation from the ubiquitin chain so that it can gain access to the proteasome and the generation of free monomeric ubiquitin that is then available for further cycles of the ubiquitin system. Thus, UCH-L1 deficiency impairs ubiquitin-dependent protein degradation and results in accumulation of highly ubiquitinated proteins (27–29).
Given the parallels between neurons in neurodegenerative diseases and islets in type 2 diabetes, we hypothesized that the ERAD/ubiquitin/proteasome system is compromised in β-cells in type 2 diabetes. Further, we hypothesized that increased expression of amyloidogenic h-IAPP would reproduce this dysfunction. Finally, we postulated that the specific mechanism subserving the compromised ERAD/ubiquitin/proteasome system in β-cells in type 2 diabetes, and as a consequence of increased expression of h-IAPP, is decreased availability of UCH-L1.
RESEARCH DESIGN AND METHODS
Rat insulinoma cell line INS 832/13 was provided by Dr. C. Newgard (Durham, NC) (30). For the transduction experiments, cells were plated on six-well plates at 106 cells/well, cultured for 24 h, and transduced with r-IAPP or h-IAPP adenoviruses at 400 multiplicity of infection (MOI) for 48 h. At the end of the experiment, cells were lysed for 30 min at 4°C in a solubilizing buffer (31).
Animal model: pancreas processing and islet isolation.
The generation of h-IAPP transgenic rats (HIP rats) has been described previously (10). Rats were bred and housed at the animal housing facility of the University of California Los Angeles (UCLA). The UCLA Institutional Animal Care and Use Committee approved all surgical and experimental procedures. For immunofluorescence, wild-type and HIP rats (2 months old) were randomly assigned to either a high-fat diet (HFD) (60% fat, 20% protein, and 20% carbohydrates; Research Diets, New Brunswick, NJ) or a control regular diet (10% fat, 20% protein, and 70% carbohydrates; Research Diets) and were fed ad libitum for 10 weeks (6) (supplementary Table 3 in the online appendix, available at http://diabetes.diabetesjournals.org/cgi/content/full/db10-0522/DC1). Pancreata were fixed with 4% paraformaldehyde (Sigma), paraffin embedded, and cut into 4-μm sections. Islets were obtained from 4- to 6-month-old wild-type (fasting blood glucose [FBG] 77 ± 4 mg/dl) and prediabetic HIP rats (FBG 87 ± 4 mg/dl) (as described in 16). Islets were lysed in lysis buffer (50 mmol/l HEPES, 1% Nonidet P-40, 2 mmol/l Na3VO4, 100 mmol/l NaF, 10 mmol/l PyrPO4, 4 mmol/l EDTA, 1 mmol/l PMSF, 1 μg/ml leupeptin, and 1 μg/ml aprotinin), sonicated for 10 s, centrifuged, and stored at −20°C until use for subsequent protein determination by bicinchoninic acid assay (Bio-Rad, Hercules, CA) and Western blotting.
Isolated human islets were obtained from the Islet Cell Resource Consortium (http://icr.coh.org). The islet purity was 90–95%, as assessed by dithizone staining. Islets used for transduction experiments were obtained from nine heart-beating organ donors (five men and four women, 45 ± 15 years of age, BMI 28 ± 5 kg/m2), and none had a previous history of diabetes or metabolic disorders. Islet viability was 80–95%, as assessed by the live/dead kit (Invitrogen). Islets were transduced with r-IAPP or h-IAPP adenoviruses at 400 MOI for 72 h in RPMI-1640 medium containing 100 units/ml of penicillin, 100 μg/ml of streptomycin, and 10% FBS (Invitrogen). Islets used for analysis of ubiquitin or UCH-L1 expression were obtained from four heart-beating organ donors with type 2 diabetes and three BMI-matched nondiabetic control subjects (supplementary Table 1).
Human pancreatic tissue.
Institutional review board approval was obtained from the Mayo Clinic (no. 1516-03) and UCLA (no. 06-04-021-01). We obtained human pancreatic tissue at autopsy from 6 lean nondiabetic subjects, 10 obese subjects with type 2 diabetes, and 5 BMI-matched nondiabetic control subjects (supplementary Table 2). Pancreas samples from subjects with type 2 diabetes were from individuals who had been treated with diet alone and/or sulfonylurea treatment (FBG 172 ± 26 mg/dl) or diet and insulin therapy (FBG 213 ± 49 mg/dl). Pancreatic sections were stained with an anti-ubiquitin antibody and stained in parallel for insulin to identify β-cells. We obtained nontumor-involved pancreatic tissue following surgical pancreatectomy for pancreatic tumors from three nondiabetic humans and three obese humans with type 2 diabetes (supplementary Table 4). Pancreas was processed as previously described (1).
Proteins (25–50 μg/lane) were separated on a 4–12% Bis-Tris NuPAGE gel and blotted onto a nitrocellulose membrane (Whatman, Germany). Membranes were probed overnight at 4°C with primary antibodies against Poly (ADP-ribose) polymerase (PARP), phospho-eIF2-α (Ser51), β-actin, glyceraldehyde 3-phosphate dehydrogenase (GAPDH), and ubiquitin from Cell Signaling Technology (Beverly, MA); human ubiquitin from R&D Systems; ubiquitin (clone FK2) from Biomol International (Plymouth Meeting, PA); UCH-L1 from Chemicon International (Temecula, CA); β-tubulin from Sigma; C/EBP homologous protein (CHOP) from Santa Cruz Biotechnology (Santa Cruz, CA); IAPP (25–37 aa) from Peninsula Laboratories (San Carlos, CA); and insulin from Zymed Laboratories (San Francisco, CA). For detection of apoptosis, membranes were probed with an antibody against the cleaved form of caspase-3 (Cell Signaling Technology). We consider cleaved caspase-3 as a reliable marker because a variety of alternative approaches have been previously used in line with cleaved caspase-3 to support emergence of apoptosis in the same models (1,6,32). Horseradish peroxidase–conjugated secondary antibodies were from Zymed Laboratories. Proteins were visualized by enhanced chemiluminescence (Millipore), and protein expression levels were quantified using the Labworks software (UVP, Upland, CA).
Proteasome activity assay.
Proteasome activity was assessed using the 20S proteasome activity assay kit (Chemicon International) according to the manufacturer's protocol. Detection was made by spectrofluorometry (BioTek Flx800), with excitation and emission wavelengths at 380 and 460 nm, respectively. The optical density values were normalized to the protein content.
UCH-L1 expression was silenced in INS 832/13 cells using 25-nucleotide stealth-prevalidated siRNA duplexes designed for rat UCH-L1 (Invitrogen). Cells were seeded in 12-well plates and grown overnight to reach 40–50% confluency. The next day, lipofectAMINE2000-siRNA complexes were prepared according to the manufacturer's instructions. UCH-L1 siRNA duplexes were tested at final concentrations of 25 (0.12 μg), 50 (0.24 μg), or 100 nmol/l (0.48 μg). Cells were transfected with UCH-L1 siRNA or control siRNA (scramble) in Opti-MEM (Invitrogen) for 6 h before switching to fresh culture medium; cells were lysed 24, 48, or 72 h after transfection.
INS 832/13 cells were plated in four-well chamber permanox slides (Nunc, Rochester, NY) at 100,000 cells per well. After the treatment (as indicated), the immunofluorescence procedure was performed as described in 33. Cells were incubated overnight at 4°C with anti-CHOP antibody, followed by a 1-h treatment with secondary antibody conjugated to Cy3 (Jackson ImmunoResearch Laboratories, West Grove, PA). Slides were viewed using a Leica DM6000 microscope (Leica Microsystems, Bannockburn, IL) and imaged using Openlab software (Improvision, Lexington, MA). The immunofluorescence of rat and human tissues was as described (1).
For detailed evaluation of β-cells positive for ubiquitin, 15 islets per case were selected randomly. The β-cell was considered to be positive if it had any labeling with intensity above background staining of exocrine pancreas. For the quantification of CHOP immunostaining, images of six randomly chosen fields were taken at ×10 magnification. The cells containing nuclear CHOP labeling with intensity above background and the total number of cells in each field were counted. Results were expressed as the percentage of CHOP-positive cells.
Results are expressed as the means ± SE for n independent experiments, as indicated in figure legends. Statistical analyses were carried out by Student t test or ANOVA followed by Fisher post hoc test for multiple comparisons using Statistica (Statsoft, Tulsa, OK). A P value of <0.05 was taken as evidence of statistical significance (*P < 0.05; **P < 0.01; ***P < 0.001).
Accumulation of polyubiquitinated proteins in β-cells of humans with type 2 diabetes abrogated by insulin therapy.
To test the hypothesis that the ERAD/ubiquitin/proteasome system is dysfunctional in type 2 diabetes, we first examined pancreatic tissue and isolated islets from humans with type 2 diabetes versus BMI-matched control subjects (supplementary Tables 1 and 2). The percentage of β-cells immunostained for ubiquitin was unchanged by obesity in nondiabetic individuals (6.8 ± 2.9% vs. 2.1 ± 1.3%, P = NS, obese nondiabetic vs. lean nondiabetic) (Fig. 1A and B), implying that in health, the β-cell ERAD/ubiquitin/proteasome system adapts to the increased synthetic burden of insulin and IAPP prompted by obesity-mediated insulin resistance (6,7). In contrast, the percentage of β-cells with ubiquitin immunostaining was increased (approximately fourfold) in obese individuals with type 2 diabetes treated with diet and/or sulfonylureas in comparison to obese nondiabetic individuals (25 ± 6% vs. 6.8 ± 2%, P < 0.05) (Fig. 1A and B). Ubiquitin immunostaining in islets was mostly cytoplasmic, although nuclear staining was also found in some cells, consistent with previous reports documenting the presence of components of the ubiquitin-proteasome pathway in both cytoplasmic and nuclear compartments (34) and implying that defective protein degradation may also alter clearance of nuclear proteins.
Western blot analysis of isolated islets obtained from three individuals with type 2 diabetes and three BMI-matched nondiabetic control subjects (supplementary Table 1) revealed high–molecular weight smears that correspond to polyubiquitinated proteins (Fig. 1C). A stronger ubiquitin signal was detected in islets from individuals with type 2 diabetes (Fig. 1C), corroborating the increased ubiquitin staining detected by immunohistochemistry of pancreas sections from humans with type 2 diabetes.
Interestingly, we found that the percentage of β-cells positive for ubiquitin in obese individuals with type 2 diabetes treated with insulin was decreased in comparison to individuals treated with diet only or oral sulfonylureas (3.6 ± 1.4% vs. 25 ± 6%, P < 0.01) (Fig. 1A and B), perhaps through the decreased ER synthetic burden mediated by exogenous insulin. IAPP production would be an interesting parameter to follow in this study. Unfortunately, it is not available for these groups of subjects, and relative expression rates can only be inferred from animal studies.
Because accumulation of polyubiquinated proteins in neurodegenerative diseases has been attributed to dysfunction of the ERAD/ubiquitin/proteasome rendered by accumulation of amyloidogenic proteins, we next investigated whether the accumulation of polyubiquitinated proteins in β-cells is induced by increased expression of amyloidogenic h-IAPP.
Pancreatic β-cells from HIP rats display high levels of ubiquitinated proteins associated with decreased UCH-L1 protein expression.
We studied 4- to 6-month-old h-IAPP transgenic rats (HIP rat) versus wild-type rats. At this age, HIP rats have increased β-cell apoptosis but do not yet have diabetes, allowing us to avoid the confounding effects of glucose toxicity (research design and methods) (10,14). The percentage of β-cells immunostained for ubiquitin was increased in HIP rats (32 ± 5% vs. 8 ± 5%, P < 0.01) (Fig. 2A and B). The staining was mostly cytoplasmic, although nuclear staining was also evident in some cells (Fig. 2A). To draw a parallel between obese individuals with type 2 diabetes and the rat model, we also examined pancreatic sections from HFD-fed HIP rats (6). Within this group of HFD-fed HIP rats, which have diabetes and are insulin resistant, the percentage of β-cells stained for ubiquitin was increased in comparison to HIP rats fed with a regular diet (50 ± 3% vs. 32 ± 5%, P < 0.05) (Fig. 2B). Ubiquitin immunostaining was predominantly cytoplasmic, although nuclear staining was present in some cells, comparable to islets in type 2 diabetes (Fig. 1A). Impaired proteasome function may cause accumulation of ubiquitinated proteins (18). However, proteasome activity was comparable in islets of HIP, HFD-fed HIP, and wild-type rats (Fig. 2C).
UCH-L1 permits ubiquitinated proteins to access the proteasome and when deficient may lead to accumulation of polyubiquinated proteins (27–29). Therefore, we next investigated UCH-L1 expression in HIP rat islets. UCH-L1 protein levels were decreased by 42 ± 9% in islets of HIP compared with wild-type rats (P < 0.01) (Fig. 3B). UCH-L1 mRNA levels were also downregulated by 28 ± 6% in HIP rat islets (P < 0.05) (Fig. 3C). This downregulation was supported by microarray analysis of HIP versus wild-type rat islets (data not shown). These results suggest that decreased UCH-L1 protein expression occurred, at least in part, at a transcriptional level. Accumulation of ubiquitinated proteins (Fig. 3A) and decreased UCH-L1 protein expression were also related to ER stress and apoptosis in HIP rat islets, as shown by increased CHOP expression and increased cleaved caspase-3 respectively (Fig. 3B) (6). Also, the frequency of β-cells positive for ubiquitin was highly correlated to β-cell ER stress and β-cell apoptosis (r = 0.8, P < 0.001, and r = 0.7, P < 0.01, respectively) (supplementary Fig. 1A and B). These data suggest that high expression rates of h-IAPP lead to the accumulation of ubiquitinated proteins and downregulation of UCH-L1 in vivo.
h-IAPP but not r-IAPP expression decreases UCH-L1 protein level in β-cells.
To establish whether UCH-L1 downregulation is caused by h-IAPP, we studied INS 832/13 cells transduced with adenoviruses expressing h-IAPP or the nonamyloidogenic and nontoxic rodent IAPP (r-IAPP), as control for a comparable burden of protein expression (33). Cells transduced with h-IAPP (400 MOI, 48 h) exhibited a 31 ± 10% decrease in UCH-L1 protein expression in comparison to r-IAPP-transduced cells (P < 0.05) (Fig. 4). Therefore, high expression rates of h-IAPP lead to UCH-L1 downregulation in β-cells, and this effect is due to the amyloidogenic properties of h-IAPP rather than just protein overload.
Loss of UCH-L1 function and expression leads to ER stress and β-cell apoptosis.
To evaluate whether UCH-L1 downregulation plays a role in the progression of h-IAPP–induced β-cell apoptosis, we treated INS 832/13 cells with UCH-L1 inhibitor, LDN-57444, for 18 h at different concentrations. Inhibition of UCH-L1 function led to increased caspase-3 activity and cleavage at concentrations above 30 μmol/l (Fig. 5A and B). We next investigated whether apoptosis induced by UCH-L1 inhibitor was related to ER stress. Western blot analysis showed induction of CHOP after exposure to UCH-L1 inhibitor (Fig. 5B) and immunostaining revealed that nuclear CHOP was highly induced in LDN-57444–treated cells (13.4 ± 0.4% vs. 2.5 ± 0.8%, P < 0.01) (Fig. 5C). An increased phosphorylation of eukaryotic initiation factor 2 (eIF2)-α, a target of Perk and ER stress marker, was also detected by Western blot (supplementary Fig. 2A).
To further corroborate these findings, we used a siRNA approach to specifically target UCH-L1 and decrease its expression. Transfection of INS 832/13 cells using 25 nmol/l of siRNA resulted in 44 ± 6% knockdown of UCH-L1 protein content (Fig. 6A and B), reproducing the deficit observed in HIP rat islets (Fig. 3B). This decrease in protein content was associated with a decrease in UCH-L1 activity (Fig. 6A and B), as shown by labeling studies using Ub-VS active site probe for deubiquitinating enzymes. This probe (with an HA tag) covalently modifies active deubiquitinating enzymes in the extracts. Examination of Ub-VS–treated extracts from control or scramble-transfected cells revealed several HA reactive bands, including a 35-kDa band corresponding to UCH-L1 complexed with the probe (35). This band was decreased by ∼40% in UCH-L1 siRNA-transfected cells (Fig. 6A and B), confirming a decrease in active UCH-L1. This decrease in UCH-L1 protein content and activity led to increase of cleaved caspase-3 and of its cleaved substrate PARP (Fig. 6A and B). Immunostaining revealed that nuclear CHOP was highly induced in UCH-L1–downregulated cells in comparison to scramble-transfected cells (23 ± 3% vs. 6.3 ± 1.3%, P < 0.01) (Fig. 6C). ER stress was also confirmed by the increase in eIF2-α phosphorylation upon UCH-L1 downregulation (supplementary Fig. 2B). In conclusion, chemical inhibition as well as knockdown of UCH-L1 leads to accumulation of ubiquitinated proteins (supplementary Fig. 3), ER stress, and apoptosis in β-cells.
To determine whether a decrease in UCH-L1 exacerbates h-IAPP–induced apoptosis, we transfected INS 832/13 cells with UCH-L1 siRNA or scramble (25 nmol/l, 36 h) and transduced these cells with h-IAPP or r-IAPP adenoviruses at 300 MOI for 30 h. Under these conditions, neither UCH-L1 siRNA nor h-IAPP alone induced cell death as illustrated by cleaved caspase-3 and cleaved PARP levels (supplementary Fig. 4A and B) or caspase-3 activity (data not shown). UCH-L1 knockdown increased the cleavage of caspase-3 and PARP in both r-IAPP– and h-IAPP–transduced cells in comparison to scramble-transfected cells. However, when UCH-L1 was knocked down in the presence of h-IAPP, cell death was induced to a greater extent in comparison to r-IAPP–transduced cells (supplementary Fig. 4A and B, lane 8 vs. lane 9, P < 0.001). These results demonstrate the critical role of UCH-L1 for β-cell survival under conditions of a high protein synthetic burden.
Increased expression of h-IAPP in isolated human islets leads to accumulation of polyubiquitinated proteins associated with decreased UCH-L1 protein level.
To establish whether h-IAPP affects the ubiquitin/proteasome pathway in human β-cells, we transduced isolated human islets with adenoviruses expressing h-IAPP or r-IAPP (400 MOI, 72 h). The accumulation of polyubiquitinated proteins was significantly increased (1.8 ± 0.1-fold, P < 0.01) in human islets transduced with h-IAPP, as shown by Western blot analysis (Fig. 7A). To address the mechanism by which h-IAPP leads to the accumulation of ubiquitinated proteins in human islets, we examined its actions on proteasome activity as well as on UCH-L1 expression. There was no change in proteasome activity in human islets transduced with h-IAPP in comparison to islets transduced with r-IAPP (Fig. 7B). However, overexpression of h-IAPP led to a 40 ± 5% decrease in UCH-L1 protein expression (P < 0.01) (Fig. 7C), supporting the data obtained in both HIP rat islets (Fig. 3B) and INS 832/13 cells (Fig. 4) and suggesting that a specific property of h-IAPP is responsible for accumulation of polyubiquitinated proteins and UCH-L1 downregulation in human β-cells.
UCH-L1 protein level is decreased in β-cells of individuals with obesity and type 2 diabetes.
To investigate whether UCH-L1 deficiency occurs in individuals with type 2 diabetes, we examined protein levels in isolated islets obtained from three obese nondiabetic (OND group) and three obese individuals with type 2 diabetes (OD group) (supplementary Table 1). Western blot analysis of these samples showed decreased UCH-L1 protein levels normalized to β-tubulin in individuals with type 2 diabetes versus BMI-matched nondiabetic control subjects. Insulin protein levels were also decreased in obese individuals with type 2 diabetes, and this may either reflect diminished number of β-cells per islet and/or depleted insulin stores per β-cell. UCH-L1 protein levels in type 2 diabetes remain decreased even when normalized to insulin (46 ± 14%, P < 0.05) (Fig. 8A), presumably a conservative estimate of the extent of the deficit.
In addition, analysis of pancreata stained by immunofluorescence for UCH-L1 revealed diminished staining of β-cells in individuals with type 2 diabetes in comparison to nondiabetic individuals (Fig. 8B) (supplementary Table 4). These observations support the data obtained by Western blot, indicating that UCH-L1 protein levels are decreased in β-cells of individuals with type 2 diabetes. Interestingly, UCH-L1 protein expression was inversely related to the accumulation of polyubiquitinated proteins in β-cells of individuals with type 2 diabetes (Fig. 1C). Taken together, these data reveal that decreased UCH-L1 availability and accumulation of poyubiquitinated proteins are characteristics of β-cells in type 2 diabetes.
We report that the ERAD/ubiquitin/proteasome system is dysfunctional in β-cells of individuals with type 2 diabetes as demonstrated by the accumulation of polyubiquinated proteins. This further supports that islet dysfunction in type 2 diabetes and neuronal dysfunction in neurodegenerative diseases share common mechanisms. In most neurodegenerative diseases, dysfunction of the ERAD/ubiquitin/proteasome system is a consequence of amyloidogenic protein aggregates that, by disrupting this system, further compound their adverse actions (23). An intriguing finding in our studies supports that model. Accumulation of polyubiquinated proteins was decreased in β-cells of individuals with type 2 diabetes treated with insulin therapy in comparison to those treated by sulfonylureas and diet therapy, even though the blood glucose control was comparable. Insulin therapy might thus be expected to protect β-cells against dysfunction of the ERAD/ubiquitin/proteasome system by reducing the synthetic burden for both insulin and IAPP in type 2 diabetes.
Having established that the ERAD/ubiquitin/proteasome system is compromised in β-cells of humans with type 2 diabetes, we sought to examine if this can be reproduced by increased h-IAPP expression. Moreover, we sought to establish if the underlying defect is at the proteasome level or because of decreased UCH-L1 availability. We report that UCH-L1 protein levels are decreased in β-cells of humans with type 2 diabetes, and this is accompanied by accumulation of ubiquitin conjugates. Hyperglycemia, per se, can lead to decreased UCH-L1 expression (25), but our data suggest that h-IAPP misfolding has an independent action on UCH-L1 expression and function. We examined islets from HIP rats at 4 to 6 months of age before this model develops diabetes but already has β-cell dysfunction (10,14). In those studies, as well as those with isolated human islets and INS 832/13 cells expressing h-IAPP versus r-IAPP, the actions of h-IAPP to compromise UCH-L1 availability were documented independently of glucose toxicity. Moreover, dysfunction of the ERAD/ubiquitin/proteasome system with decreased UCH-L1 availability in neurodegenerative diseases characterized by misfolded amyloidogenic proteins occurs in the absence of diabetes. Therefore, we speculate that the defect in protein degradation apparent in β-cells in type 2 diabetes can, at least in part, be attributed to misfolded h-IAPP leading to UCH-L1 deficiency, which in turn likely further compromises β-cell viability by exacerbating ER stress.
These findings raise the question, how does amyloidogenic h-IAPP lead to decreased UCH-L1 availability? UCH-L1 mRNA and protein expression were decreased in HIP rat islets, but the mechanisms responsible for this downregulation remain to be elucidated. UCH-L1 transcriptional repression was shown to be mediated through CpG hypermethylation of its promoter in renal cells (36). Interestingly, ER stress induces transcriptional repression through promoter hypermethylation (37). Therefore, h-IAPP–mediated ER stress could lead to hypermethylation of the UCH-L1 gene promoter, leading to decreased mRNA and protein levels. Post-transcriptional and post-translational modifications of UCH-L1 might also account for decreased UCH-L1 availability. In neurons from individuals with Alzheimer's or Parkinson's disease, UCH-L1 protein expression is decreased and is also a major target of oxidative damage (24). UCH-L1 is thus extensively modified by carbonyl formation, leading to alteration of its activity (38). β-Cells are highly vulnerable to oxidative stress that is a characteristic in type 2 diabetes (39). Because h-IAPP oligomers disrupt β-cell mitochondrial integrity (15), it is likely that h-IAPP contributes to β-cell oxidative stress (40) that is compounded by subsequent hyperglycemia. We conclude that h-IAPP oligomers may induce UCH-L1 deficiency by decreasing UCH-L1 gene expression and/or by the way of post-translational modifications mediated through oxidative damage.
Although we reproducibly demonstrated that h-IAPP induced UCH-L1 downregulation in different models, endogenous h-IAPP expression did not decrease proteasome activity. Proteasome activity was decreased in human islets incubated with applied exogenous h-IAPP (41). This discrepancy can be explained by the differences between exogenously applied h-IAPP (41) and endogenously expressed h-IAPP. Application of toxic protein oligomers extracellularly bypasses the ERAD/ubiquitin/proteasome system for removal of toxic oligomers as they are formed. The overwhelming actions of this approach induce apoptosis in most cells within 24 h (9). However, data are accumulating to suggest that toxic h-IAPP oligomers form intracellularly in some β-cells in type 2 diabetes (15) and have a more subtle effect on β-cell viability and function as described in animal models that develop diabetes through transgenic expression of h-IAPP (42).
The lack of an adverse effect of endogenously expressed h-IAPP on proteasome catalytic activity suggests that h-IAPP compromises the ubiquitin/proteasome system upstream of the proteasome. Because ubiquitinated proteins accumulate with increased h-IAPP, we considered that the ubiquitination process itself is unlikely to be perturbated. A more plausible explanation for accumulation of ubiquinated proteins with increased expression of h-IAPP is compromised delivery of ubiquitinated proteins to the proteasome. Degradation of proteins targeted for proteasomal degradation may be altered by abnormal modifications of substrates, per se, impairing their binding and/or recognition by the functional 20S proteasome. Thus, accumulation of ubiquitinated proteins may be a consequence of inhibition of deubiquitinating activity rather than direct effect on the proteasome (43). We hypothesized that in β-cells expressing h-IAPP, deficient UCH-L1 availability might lead to impaired polyubiquitin removal from proteins targeted for degradation before entry into the 20S proteasome, leading to the obstruction of the 20S pore by a forked substrate. Consistent with this hypothesis, we and others have demonstrated that inhibition of UCH-L1 led to accumulation of ubiquitinated proteins (27–29).
Modification of a protein with ubiquitin chains is the hallmark of protein degradation by the proteasome. However, recent data imply a role for ubiquitin in lysosome-dependent degradation, known as autophagy (44). In rodent β-cells, defects in autophagy are associated with accumulation of polyubiquitinated proteins (45–47). Also, β-cells in type 2 diabetes show evidence of altered autophagy (48). Interestingly, the intracellular storage of ubiquitinated aggregates in patients with lysosomal storage disorders is associated with deficiency of UCH-L1 (28). Recently, the p62/autophagy/lysosomal degradation system, an alternative mechanism to clear ubiquinated proteins, was shown to be compromised by high expression of h-IAPP (32). Given the approximately 40% decreased availability of UCH-L1 protein (and possibly further decreased function through post-translational modifications, vida supra) and impaired autophagy in β-cells in type 2 diabetes (48), both major pathways for removal of misfolded proteins are dysfunctional. Moreover, the rate of formation of misfolded proteins per β-cell requiring degradation is likely increased given the conditions of insulin resistance and decreased β-cell number as well as compromised ER function arising from ER stress and disrupted ER Ca2+ homeostasis induced by membrane permeant oligomers (15,33) and glucolipotoxicity.
Arguments in favor of a relatively early role of impaired β-cell protein homeostasis include the early presence of impaired β-cell function that precedes type 2 diabetes (49), reproduced in the HIP rat (14). However, increased expression of h-IAPP upon obesity is insufficient alone to explain why ∼20% of individuals with morbid obesity develop type 2 diabetes, whereas 80% do not. The contributor factors that may explain this include variance between individuals in the efficiency of protein chaperoning through the secretory pathway and variance in the β-cell mass accomplished during postnatal expansion. The latter results in a wide range of β-cell mass in young adults (50) and therefore presumably β-cell synthetic burden in individuals that subsequently become obese.
Because elimination of misfolded proteins is important for cell viability, we investigated the effects of UCH-L1 availability on β-cell viability. High expression of h-IAPP induces β-cell apoptosis through the mechanism of ER stress (1,16), but the precise molecular events triggering ER stress are unknown. Here, we show that increased expression of h-IAPP (but not r-IAPP) decreased UCH-L1 levels and that loss of UCH-L1 expression and activity induced ER stress and apoptosis in β-cells. Therefore, increased h-IAPP expression induces ER stress and β-cell apoptosis that is mediated, at least in part, by abnormal function of UCH-L1. In addition, the accumulation of ubiquitinated proteins might also exacerbate ER stress (51). It is likely that the tipping point from compromised β-cell function to β-cell apoptosis is driven by this unsustainable cycle once UCH-L1 function and the back up pathway of autophagy are attenuated.
In summary, we report that β-cells in type 2 diabetes share the characteristics of affected neurons in Alzheimer's and Parkinson's diseases with attenuated UCH-L1 protein levels and accumulation of ubiquitin conjugates. Increased expression of h-IAPP in β-cells, as occurs in insulin resistant states such as obesity, can lead to the formation of h-IAPP toxic oligomers and accumulation of polyubiquitinated proteins associated with decreased UCH-L1 availability. Downregulation of UCH-L1 expression and activity in β-cells induces ER stress and apoptosis. We conclude that a defective protein degradation system in β-cells in type 2 diabetes can, at least in part, be attributed to misfolded h-IAPP leading to UCH-L1 deficiency, which in turn further compromises β-cell viability.
These studies were supported by grants from the National Institutes of Health (DK059579) and the Larry L. Hillblom Foundation (2007-D-003-NET and 2008-D-027-FEL [to S.C.]).
No potential conflicts of interest relevant to this article were reported.
S.C. designed and performed the experiments and wrote the manuscript. C.-j.H., T.G., M.D., A.V.M., R.A.R., and A.E.B. contributed to the experiments and reviewed/edited the manuscript. P.C.B. contributed to the discussion and wrote, reviewed, and edited the manuscript.
We thank Chang Liu, Heather Cox, and Ryan Galasso at the Larry Hillblom Islet Research Center for their excellent technical help.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
- Received April 12, 2010.
- Accepted October 14, 2010.
- © 2011 by the American Diabetes Association.
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.